<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00028743</url>
  </required_header>
  <id_info>
    <org_study_id>OV16</org_study_id>
    <secondary_id>CAN-NCIC-OV16</secondary_id>
    <secondary_id>EORTC-55012</secondary_id>
    <secondary_id>GEICO-0101</secondary_id>
    <secondary_id>CDR0000069129</secondary_id>
    <nct_id>NCT00028743</nct_id>
  </id_info>
  <brief_title>Comparison of Combination Chemotherapy Regimens in Treating Newly Diagnosed Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer</brief_title>
  <official_title>A Phase III Study of Cisplatin Plus Topotecan Followed by Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Carboplatin as First Line Chemotherapy in Women With Newly Diagnosed Advanced Epithelial Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Grupo Español de Investigación en Cáncer de Ovario</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Combining more than one drug and giving the drugs in different
      combinations may kill more tumor cells. It is not yet known which combination chemotherapy
      regimen is more effective in treating ovarian epithelial, primary peritoneal, or fallopian
      tube cancer.

      PURPOSE: Randomized phase III trial to compare the effectiveness of different combination
      chemotherapy regimens in treating patients who have stage IIB, stage III, or stage IV ovarian
      epithelial cancer , primary peritoneal cancer, or fallopian tube cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the efficacy of cisplatin and topotecan followed by paclitaxel and carboplatin
           vs paclitaxel and carboplatin only, in terms of time to disease progression, in patients
           with newly diagnosed stage IIB-IV ovarian epithelial, primary peritoneal, or fallopian
           tube cancer.

        -  Compare the overall survival of patients treated with these regimens.

        -  Compare the clinical objective response rates in patients with measurable disease at
           baseline treated with these regimens.

        -  Compare the toxic effects of these regimens in these patients.

        -  Compare the CA 125 normalization rates in patients treated with these regimens.

        -  Compare the quality of life of patients treated with these regimens.

      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to
      participating center, age (65 years and under vs over 65 years), and pre-randomization
      surgery (no debulking vs debulking with macroscopic residual disease less than 1 cm vs
      debulking with macroscopic residual disease 1 cm or greater vs debulking with no macroscopic
      residual disease). Patients are randomized to one of two treatment arms.

        -  Arm I: Patients receive cisplatin IV over 60 minutes on day 1 and topotecan IV over 30
           minutes on days 1-5 of courses 1-4 and paclitaxel IV over 3 hours and carboplatin IV
           over 30 minutes on day 1 of courses 5-8.

        -  Arm II: Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes
           on day 1 of courses 1-8.

      In both arms, courses repeat every 21 days in the absence of disease progression or
      unacceptable toxicity. Planned interval debulking surgery should occur after course 3 or 4.

      Quality of life is assessed at baseline; on day 1 of courses 3, 5, and 7; at the end of the
      last course; and at 3 and 6 months after study treatment completion.

      Patients are followed every 3 months for 3 years, every 6 months for 2 years, and then
      annually thereafter.

      PROJECTED ACCRUAL: A total of 800 patients (400 per treatment arm) will be accrued for this
      study within 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2001</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Mar 2008</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Dec 2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rates</measure>
    <time_frame>March 2008</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxic Effects</measure>
    <time_frame>March 2008</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>March 2008</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CA125 Normalization Rates</measure>
    <time_frame>March 2008</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">819</enrollment>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Peritoneal Cavity Cancer</condition>
  <arm_group>
    <arm_group_label>Cisplatin, Topotecan, Paclitaxel plus Carboplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paclitaxel plus Carboplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>Arm 1 = 4 cycles vs Arm 2 = 8 cycles AUC5 (30 mins) day 1 of 21 day cycle</description>
    <arm_group_label>Cisplatin, Topotecan, Paclitaxel plus Carboplatin</arm_group_label>
    <arm_group_label>Paclitaxel plus Carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>4 cycles 50mg/m2 (60 mins) day 1 of 21 day cycle</description>
    <arm_group_label>Cisplatin, Topotecan, Paclitaxel plus Carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Arm 1 = 4 cycles vs Arm 2 = 8 cycles 175mg/m2 (3 hours) day 1 of 21 day cycle</description>
    <arm_group_label>Cisplatin, Topotecan, Paclitaxel plus Carboplatin</arm_group_label>
    <arm_group_label>Paclitaxel plus Carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topotecan hydrochloride</intervention_name>
    <description>4 cycles
.75mg/m2 (30 mins) days 1-5 of 21 day cycle</description>
    <arm_group_label>Cisplatin, Topotecan, Paclitaxel plus Carboplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed stage IIB-IV ovarian epithelial, primary peritoneal, or
             fallopian tube cancer

               -  No borderline ovarian tumors

               -  Residual disease allowed

          -  Fine needle aspiration showing an adenocarcinoma is allowed instead of open or
             true-cut biopsy if the following are true:

               -  Presence of pelvic mass AND

               -  Omental cake or other metastasis larger than 2 cm in the upper abdomen unless
                  proven stage IV disease AND

               -  Serum CA 125/carcinoembryonic antigen ratio at least 25 (if less than 25, a
                  barium enema or colonoscopy and gastroscopy or radiological examination of the
                  stomach should be negative for primary tumor within 6 weeks of study) AND

               -  Normal mammography within 6 weeks of study

        PATIENT CHARACTERISTICS:

        Age:

          -  18 to 75

        Performance status:

          -  ECOG 0-1

        Life expectancy:

          -  At least 12 weeks

        Hematopoietic:

          -  Granulocyte count at least 2,000/mm^3

          -  Platelet count at least 150,000/mm^3

        Hepatic:

          -  Not specified

        Renal:

          -  Creatinine no greater than upper limit of normal

        Cardiovascular:

          -  No clinically relevant atrial or ventricular arrhythmias

          -  No myocardial infarction (MI) within the past 6 months (pretreatment ECG as only
             evidence of MI allowed)

          -  No history of second- or third-degree heart blocks unless pacemaker implanted

          -  History of first-degree heart block allowed

        Other:

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  No complete bowel obstruction

          -  No prior allergic reaction to drugs containing Cremophor EL or compounds chemically
             related to study drugs

          -  No condition that would preclude high-volume saline diuresis

          -  No significant neurologic or psychiatric disorder that would preclude study compliance

          -  No active uncontrolled infection

          -  No neuropathy greater than grade 1

          -  No pre-existing hearing loss greater than grade 1

          -  No other concurrent serious illness or medical condition that would preclude study
             participation

          -  No other malignancy within the past 5 years except adequately treated nonmelanoma skin
             cancer or curatively treated carcinoma in situ of the cervix

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No concurrent biological response modifiers or immunotherapy

          -  No concurrent prophylactic colony-stimulating factors (CSFs)

               -  Concurrent therapeutic CSFs allowed

        Chemotherapy:

          -  No prior chemotherapy for ovarian cancer

          -  No other concurrent cytotoxic agents

        Endocrine therapy:

          -  No concurrent anticancer hormonal therapy

        Radiotherapy:

          -  No prior radiotherapy for ovarian cancer

        Surgery:

          -  No more than 6 weeks since prior planned pre-chemotherapy surgery for ovarian cancer

          -  Planned interval debulking allowed

          -  Concurrent second-look surgery allowed

        Other:

          -  No prior non-surgical therapy for ovarian cancer

          -  No other concurrent investigational drug therapy

          -  No other concurrent anticancer treatment

          -  Concurrent enrollment on CAN-NCIC-OV13/EORTC 55971 allowed
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul J. Hoskins, MD</last_name>
    <role>Study Chair</role>
    <affiliation>British Columbia Cancer Agency</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ignace B. Vergote, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Gasthuisberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Cancer Centre for the Southern Interior</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lions Gate Hospital</name>
      <address>
        <city>North Vancouver</city>
        <state>British Columbia</state>
        <zip>V7L 2L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Fraser Valley Cancer Centre</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Moncton Hospital</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 6Z8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Health Sciences Corporation</name>
      <address>
        <city>Saint John</city>
        <state>New Brunswick</state>
        <zip>E2L 4L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. H. Bliss Murphy Cancer Centre</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>AIB 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QEII Health Sciences Center</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre at Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centre of Southeastern Ontario at Kingston</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 5P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grand River Regional Cancer Centre</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <zip>N2G 1G3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Health Research Institute - General Division</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niagara Health System</name>
      <address>
        <city>St. Catharines</city>
        <state>Ontario</state>
        <zip>L2R 7C6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Cancer Center Health Sciences</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 5J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thunder Bay Regional Health Science Centre</name>
      <address>
        <city>Thunder Bay</city>
        <state>Ontario</state>
        <zip>P7B 6V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Health Network-Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Windsor Regional Cancer Centre</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 2X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PEI Cancer Treatment Centre,Queen Elizabeth Hospital</name>
      <address>
        <city>Charlottetown</city>
        <state>Prince Edward Island</state>
        <zip>C1A 8T5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM - Hopital Notre-Dame</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital du Sacre-Coeur de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUQ-Pavillon Hotel-Dieu de Quebec</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allan Blair Cancer Centre</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saskatoon Cancer Centre</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Italy</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </removed_countries>
  <results_reference>
    <citation>Hoskins PJ, Vergote I, Stuart G, et al.: A phase III trial of cisplatin plus topotecan followed by paclitaxel plus carboplatin versus standard carboplatin plus paclitaxel as first-line chemotherapy in women with newly diagnosed advanced epithelial ovarian cancer (EOC) (OV.16). A Gynecologic Cancer Intergroup Study of the NCIC CTG, EORTC GCG, and GEICO. [Abstract] J Clin Oncol 26 (Suppl 15): A-LBA5505, 2008.</citation>
  </results_reference>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>October 31, 2013</last_update_submitted>
  <last_update_submitted_qc>October 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II ovarian epithelial cancer</keyword>
  <keyword>stage III ovarian epithelial cancer</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <keyword>fallopian tube cancer</keyword>
  <keyword>peritoneal cavity cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

